Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation

Next Previous
X
Search
Trial Profile

Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilacidin (Primary)
  • Indications Stomatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Innovation Pharmaceuticals

    • Most Recent Events

    • 09 May 2018 Results presented in an Innovation Pharmaceuticals Media Release.
    • 16 Apr 2018 Additional data presented in an Innovation Pharmaceuticals Media Release.
    • 09 Apr 2018 Results of subgroup analysis assessing the effect of Brilacidin on incidence of severe oral mucositis in head and neck cancer patients receiving chemoradiation (aggressive versus non-aggressive chemotherapy regimen), presented in an Innovation Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top